Literature DB >> 7528923

Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase.

C Szabó1, G J Southan, C Thiemermann.   

Abstract

Enhanced formation of nitric oxide (NO) by both the constitutive and the inducible isoforms of NO synthase (NOS) has been implicated in the pathophysiology of a variety of diseases, including circulatory shock. Non-isoform-selective inhibition of NO formation, however, may lead to side effects by inhibiting the constitutive isoform of NOS and, thus, the various physiological actions of NO. S-Methylisothiourea sulfate (SMT) is at least 10- to 30-fold more potent as an inhibitor of inducible NOS (iNOS) in immunostimulated cultured macrophages (EC50, 6 microM) and vascular smooth muscle cells (EC50, 2 microM) than NG-methyl-L-arginine (MeArg) or any other NOS inhibitor yet known. The effect of SMT on iNOS activity can be reversed by excess L-arginine in a concentration-dependent manner. SMT (up to 1 mM) does not inhibit the activity of xanthine oxidase, diaphorase, lactate dehydrogenase, monoamine oxidase, catalase, cytochrome P450, or superoxide dismutase. SMT is equipotent with MeArg in inhibiting the endothelial, constitutive isoform of NOS in vitro and causes increases in blood pressure similar to those produced by MeArg in normal rats. SMT, however, dose-dependently reverses (0.01-3 mg/kg) the hypotension and the vascular hyporeactivity to vasoconstrictor agents caused by endotoxin [bacterial lipopolysaccharide (LPS), 10 mg/kg, i.v.] in anesthetized rats. Moreover, therapeutic administration of SMT (5 mg/kg, i.p., given 2 hr after LPS, 10 mg/kg, i.p.) attenuates the rises in plasma alanine and aspartate aminotransferases, bilirubin, and creatinine and also prevents hypocalcaemia when measured 6 hr after administration of LPS. SMT (1 mg/kg, i.p.) improves 24-hr survival of mice treated with a high dose of LPS (60 mg/kg, i.p.). Thus, SMT is a potent and selective inhibitor of iNOS and exerts beneficial effects in rodent models of septic shock. SMT, therefore, may have considerable value in the therapy of circulatory shock of various etiologies and other pathophysiological conditions associated with induction of iNOS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7528923      PMCID: PMC45460          DOI: 10.1073/pnas.91.26.12472

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat.

Authors:  B J Whittle; J Lopez-Belmonte; S Moncada
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

Review 2.  Nitric oxide: a physiologic messenger.

Authors:  C J Lowenstein; J L Dinerman; S H Snyder
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

3.  Dihydropyridine antagonists and agonists of calcium channels inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages.

Authors:  C Szabó; C Thiemermann; J R Vane
Journal:  Biochem Biophys Res Commun       Date:  1993-10-29       Impact factor: 3.575

4.  Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450.

Authors:  M D Burke; S Thompson; C R Elcombe; J Halpert; T Haaparanta; R T Mayer
Journal:  Biochem Pharmacol       Date:  1985-09-15       Impact factor: 5.858

Review 5.  The Croonian Lecture, 1993. The endothelium: maestro of the blood circulation.

Authors:  J R Vane
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1994-01-29       Impact factor: 6.237

6.  Selective hemoglobin inhibition of endothelium-dependent vasodilation of rabbit basilar artery.

Authors:  S Fujiwara; N F Kassell; T Sasaki; T Nakagomi; R M Lehman
Journal:  J Neurosurg       Date:  1986-03       Impact factor: 5.115

7.  Effects of NG-methyl-L-arginine, NG-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta.

Authors:  G A Joly; M Ayres; F Chelly; R G Kilbourn
Journal:  Biochem Biophys Res Commun       Date:  1994-02-28       Impact factor: 3.575

8.  Macrophage and endothelial cell nitric oxide synthesis: cell-type selective inhibition by NG-aminoarginine, NG-nitroarginine and NG-methylarginine.

Authors:  S S Gross; D J Stuehr; K Aisaka; E A Jaffe; R Levi; O W Griffith
Journal:  Biochem Biophys Res Commun       Date:  1990-07-16       Impact factor: 3.575

9.  Inhibition by spermine of the induction of nitric oxide synthase in J774.2 macrophages: requirement of a serum factor.

Authors:  C Szabó; G J Southan; E Wood; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

10.  Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells.

Authors:  D J Stuehr; C F Nathan
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  59 in total

1.  A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.

Authors:  L C Hamilton; I Vojnovic; T D Warner
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Expression of inducible nitric oxide synthase mRNA and nitric oxide production during the development of liver abscess in hamster inoculated with Entamoeba histolytica.

Authors:  Joel Ramírez-Emiliano; Angélica González-Hernández; Sergio Arias-Negrete
Journal:  Curr Microbiol       Date:  2005-06-13       Impact factor: 2.188

3.  Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice.

Authors:  C Conde; M Mark; F J Oliver; A Huber; G de Murcia; J Ménissier-de Murcia
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

4.  Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death.

Authors:  V E Laubach; E G Shesely; O Smithies; P A Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

5.  Abnormal activation of Na+-K+ pump in aortas from rats with endotoxaemia.

Authors:  Shiu-Jen Chen; Kao-Hsiang Chen; R Clinton Webb; Mao-Hsiung Yen; Chin-Chen Wu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-06-28       Impact factor: 3.000

6.  Changes in functional and histological distributions of nitric oxide synthase caused by chronic hypoxia in rat small pulmonary arteries.

Authors:  Mikiyasu Shirai; James T Pearson; Akito Shimouchi; Noritoshi Nagaya; Hirotsugu Tsuchimochi; Ishio Ninomiya; Hidezo Mori
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

7.  Effect of combining nicotinamide as a PARS-inhibitor with selective iNOS blockade during porcine endotoxemia.

Authors:  A Stehr; F Ploner; I Tugtekin; M Matejovic; M Theisen; C Zülke; M Georgieff; P Radermacher; K-W Jauch
Journal:  Intensive Care Med       Date:  2003-05-09       Impact factor: 17.440

8.  Endothelial glucocorticoid receptor is required for protection against sepsis.

Authors:  Julie E Goodwin; Yan Feng; Heino Velazquez; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

9.  Spontaneous rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform.

Authors:  G J Southan; B Zingarelli; M O'Connor; A L Salzman; C Szabó
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

10.  Inhibition by tetranactin of interleukin 1 beta- and cyclic AMP-induced nitric oxide synthase expression in rat renal mesangial cells.

Authors:  D Kunz; G Walker; I Wiesenberg; J Pfeilschifter
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.